Search Results
Your search for s matches 6865 pages
Showing 2651 - 2700Outcomes for Rural Patients With Cancer Enrolled in Clinical Trials
The disparity in survival rates between rural and urban patients is reduced when patients in both settings are enrolled in clinical trials, SWOG study results show. The study results were published in JAMA Network Open by a team led by Joseph Unger, PhD, a SWOG biostatistician...
Active Surveillance of Lung Subsolid Nodules May Reduce Unnecessary Surgery and Overtreatment
Subsolid nodules can be considered a biomarker of lung cancer risk, and should be managed with long-term active surveillance. Conservative management of these nodules may reduce unnecessary surgery and overtreatment in patients with multiple comorbidities and aggressive lung cancer arising from...
Gene-Expression Predictor for Immunotherapy Response in Melanoma
In a new study, researchers developed a gene expression predictor that can indicate whether melanoma in a specific patient is likely to respond to treatment with immune checkpoint inhibitors. Their research was published by Auslander et al in Nature Medicine. “There is a critical need to be...
FDA Approves Pembrolizumab in Combination With Chemotherapy for First-Line Treatment of Metastatic Nonsquamous NSCLC
Today, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) in combination with pemetrexed (Alimta) and platinum as first-line treatment of patients with metastatic, nonsquamous non–small cell lung cancer with no EGFR or ALK genomic tumor aberrations. Pembrolizumab...
Impact of Doctor-Patient Communication on Outcomes in Cancer Survivors
A new study from the American Cancer Society has found that patients with cancer who reported greater satisfaction in the way their provider communicated with them received more efficient care, with fewer office visits and better health outcomes. These findings were published by Rai et al in...
Cetuximab With Radiotherapy Found to Be Inferior to Standard Treatment in HPV-Positive Oropharyngeal Cancer
An interim analysis of data from a randomized clinical trial of patients with human papillomavirus (HPV)-positive oropharyngeal cancer found that treatment with radiation therapy and cetuximab (Erbitux) is associated with worse overall and progression-free survival compared to the current standard...
Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide in Pediatric Intermediate-Risk Rhabdomyosarcoma
In a phase III Children’s Oncology Group study reported in the Journal of Clinical Oncology, Hawkins et al found that substituting vincristine and irinotecan (VI) for half of vincristine, dactinomycin, and cyclophosphamide (VAC) courses did not improve event-free survival in pediatric...
Functional and Social Independence in Survivors of Pediatric CNS Tumors
In a report from the St. Jude Lifetime Cohort Study published in the Journal of Clinical Oncology, Brinkman et al found that 60% of adult survivors of pediatric central nervous system (CNS) tumors do not achieve full functional or social independence in adult life. In the study, functional and...
Cannabinoids for Cancer Pain: Dangerous or Beneficial?
Cannabis has been used in health care for millennia, and its use has been well documented, albeit never definitively integrated into clinical practice. Recent societal changes and the increasing acceptance and availability of cannabis have reignited the medical and public debate around its role in...
First James O. Armitage Clinical Investigator Award Presented in Maui
Matthew S. Davids, MD, MMSc, is the recipient of the first James O. Armitage Clinical Investigator Award, presented at the 2018 Pan Pacific Lymphoma Conference in July in Maui. Dr. Davids is Director of the Lymphoma BioBank and Assistant Professor of Medicine at Dana-Farber Cancer Institute and...
Venetoclax and Beyond: Successfully Targeting BCL2
Although many agents have been able to successfully inhibit the proliferative capacity of cancer cells or disable mutations that spur cancer growth, one area that has proven elusive is the apoptotic pathway—the cell’s means of resisting death. That is until recently. Dysregulation of B-cell...
Small Study Looks at Physician-Patient Discussions About Lung Cancer Screening
National guidelines advise doctors to discuss the benefits and harms of lung cancer screening with high-risk patients. A small study (n = 14) by researchers from the University of North Carolina Lineberger Comprehensive Cancer Center reported there is a gap between what guidelines...
Unraveling the Mystery of What Gives Exceptional Responders Their Superpower
Once dismissed as rare medical miracles that overcame overwhelming odds to thwart cancer, exceptional responders to cancer treatment are now the subject of intense study. In 2015, the National Cancer Institute (NCI) announced the launch of its Exceptional Responders Initiative, with the goal of...
For Hodgkin Lymphoma, PD-1 Blockade Is Not the Final Answer
Although programmed cell death protein 1 (PD-1) blockade is highly effective in Hodgkin lymphoma, not all patients respond, and not all responses are durable. Stephen M. Ansell, MD, PhD, Chair of the Mayo Clinic Lymphoma Group and Professor of Medicine at the Mayo Clinic, Rochester, described...
Drug Combination Design for Multiple Myeloma Using an AI Platform
A multidisciplinary team of researchers from the National University of Singapore (NUS) has developed an artificial intelligence (AI) technology platform that could potentially change the way drug combinations are being designed, hence enabling doctors to determine the most effective drug...
FDA Grants Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
iCAD has announced U.S. Food and Drug Administration (FDA) clearance of its artificial intelligence software program, PowerLook Density Assessment Version 3.4, which provides an automated method of determining breast density. The software is compatible with iCAD’s digital breast...
FDA Grants Breakthrough Device Designation for Cancer Detection Liquid Biopsy
PapGene, Inc, has announced their cancer detection test has received Breakthrough Device designation from the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA). The PapGene test is a multianalyte test that uses a combination of circulating tumor DNA...
Assay Uses Big Data to Predict Responses to Immunotherapy
In the age of big data, cancer researchers are discovering new ways to monitor the effectiveness of immunotherapy treatments. Researchers at the Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy developed a new way to use bioinformatics as a gathering tool to determine how ...
Why Do You Live to Conquer Cancer? Join New ASCO Campaign to Share Your Story!
ASCO RECENTLY launched its new “I Live to Conquer Cancer” national outreach and awareness campaign to draw attention to the critical importance of federally funded cancer research. Through a series of compelling videos and written stories, “I Live to Conquer Cancer” puts a human face on cancer...
ASCO Annual Meeting Merit Awards: This Year’s Winners
The Conquer Cancer Merit Awards support oncology trainees who are first authors on abstracts selected for presentation at an ASCO scientific meeting, including the ASCO Annual Meeting and thematic symposia. Conquer Cancer recognized 127 recipients with Merit Awards at the 2018 ASCO Annual Meeting,...
TAILORx: How to Apply This Landmark Study
TAILORx changes the configuration of the ball field and the shape of the ball in deciding which women will be recommended chemotherapy after resection of node-negative, hormone receptor–positive breast cancer. TAILORx was presented by Joseph Sparano, MD, at the 2018 ASCO Plenary Session and...
CXCR4 Antagonist Plus Eribulin in HER2-Negative Metastatic Breast Cancer
Findings in a phase I trial reported in The Lancet Oncology by Pernas and colleagues indicate activity of the combination of the CXCR4 chemokine receptor antagonist balixafortide plus eribulin (Halaven) in previously treated HER2-negative metastatic breast cancer. The CXCR4–stromal cell-derived...
ASCO and Friends Submit Recommendations to FDA Aimed at Reducing Barriers to Clinical Trial Participation
ASCO and Friends of Cancer Research (Friends) have submitted recommended language to the U.S. Food and Drug Administration (FDA) for five guidance documents on ways to broaden eligibility criteria for cancer clinical trials. The recommendations are part of an ASCO...
Guidelines for Pediatric CAR T-Cell Therapy Developed
Almost 1 year after the U.S. Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children with acute lymphoblastic leukemia (ALL), researchers at The University of Texas MD Anderson Cancer Center and the Pediatric Acute Lung Injury and...
Utilization of Hypofractionated Radiation Therapy in Breast Cancer
Researchers at the Feinstein Institute for Medical Research and Northwell Health’s Department of Radiation Medicine have identified methods to increase use of the radiation therapy hypofractionation in patients with breast cancer. These findings, published by Gilbo et al...
Lung Cancer Screening Guidelines May Be Inadequate for High-Risk Minorities
Data from a lung cancer screening program at the University of Illinois at Chicago (UIC) provides evidence that national lung cancer screening guidelines, which were developed based on the National Lung Screening Trial (NLST) in 2011 and recommend screening based on age and smoking history, may be...
Reishi Mushroom
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Ting Bao, MD, DABMA, MS, and Jyothirmai Gubili, MS, present information on the use of reishi...
FDA Approves Mogamulizumab-kpkc for Two Rare Types of Non-Hodgkin Lymphoma
Today, the U.S. Food and Drug Administration approved mogamulizumab-kpkc (Poteligeo) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy. This approval provides a new...
New Tool for Assessing Frailty in Patients With Newly Diagnosed Multiple Myeloma
A NEW “frailty index” may predict overall survival for patients newly diagnosed with multiple myeloma, according to a study published in JCO Clinical Cancer Informatics.1 Frailty is a critical factor in treatment decision-making for many patients with multiple myeloma, as many of these patients are ...
New Frontiers Being Explored in Multiple Myeloma
BEFORE TOO LONG, oncologists can expect to have an entirely new arsenal in the fight against multiple myeloma. Cutting-edge therapies on the near horizon were described in a presentation by Kenneth Anderson, MD, at the 2018 American Association of Cancer Research’s (AACR’s) inaugural conference on...
Why Oncologists Should Decline to Participate in the Right to Try Act
ON MAY 30, 2018, President Donald J. Trump signed into law the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017.1 This law creates an additional and alternative pathway for patients with a “life-threatening disease or condition” to access...
Screening for Financial Issues in Adult Survivors of Childhood Cancer
Adult survivors of childhood cancer should be screened for financial problems that might cause them to delay or skip medical care or to suffer psychological distress. The recommendation from St. Jude Children’s Research Hospital researchers followed an analysis that found 65% of...
careHPV Test Receives WHO Prequalification Status for Cervical Cancer Screening
The careHPV Test, a molecular diagnostic for high-risk human papillomavirus (HPV) designed to screen women in low-resource settings, has been added to the World Health Organization (WHO) list of prequalified in vitro diagnostics (IVDs). HPV is the primary cause of cervical cancer, so ...
Phase III ASTRAL-1 Study of Guadecitabine in Patients With Treatment-Naive AML Ineligible to Receive Intensive Induction Chemotherapy
Results were recently announced from the ASTRAL-1 study evaluating the efficacy and safety of guadecitabine in adults with previously untreated acute myeloid leukemia (AML) who are not eligible for intensive induction chemotherapy. The study did not meet its co-primary endpoints: complete...
Treatment Intensification for Childhood B-Cell Lymphoblastic Leukemia With IKZF1 Deletion
In an analysis of Asian trials reported in the Journal of Clinical Oncology, Yeoh et al found evidence that treatment intensification improved outcomes in childhood B-cell acute lymphoblastic leukemia (B-ALL) with IKZF1 deletion (del). The analysis compared outcomes in the Malaysia-Singapore ALL...
Abemaciclib as Initial Therapy for Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Early in 2018, abemaciclib (Verzenio) in combination with an aromatase inhibitor was approved as initial endocrine-based therapy for postmenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.1,2 Supporting Efficacy Data Approval was based on findings in ...
Lung Cancer Mortality Among Women Projected to Increase by 43% Worldwide by 2030
According to a report by the International Agency for Research on Cancer, cancer is among the leading causes of morbidity and mortality worldwide, with an estimated incidence of 14 million new cases of the disease and 8.2 million cancer deaths in 2012. A study analyzing breast and female lung...
Response to Ibrutinib in Symptomatic Untreated Waldenström’s Macroglobulinemia
In a study reported in the Journal of Clinical Oncology, Treon et al found that ibrutinib monotherapy was highly active in patients with previously untreated Waldenström’s macroglobulinemia, with better response in patients without CXCR4 mutation. Ibrutinib has been shown to be active in ...
Use of Analgesics and Ovarian Cancer–Specific Survival
In a prospective cohort study reported in The Lancet Oncology, Merritt et al found evidence that recent use of aspirin or nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) after diagnosis appears to improve ovarian cancer–specific survival. Study Details The study involved...
New Tool for Assessing Frailty May Aid in Predicting Survival in Newly Diagnosed Multiple Myeloma
A new frailty index may aid in predicting overall survival for patients newly diagnosed with multiple myeloma, according to a study published by Mian et al in JCO Clinical Cancer Informatics. This tool is important because frailty is a critical factor in treatment decision-making for ...
SPOP-Mutant Prostate Cancer Subtype, High PSA, and Prognosis
Conventional wisdom suggests that a high level of the protein prostate-specific antigen (PSA) in men with prostate cancer means a poor prognosis. However, this may not always be the case in men with a particular subtype of prostate cancer, according to a new study from Weill Cornell Medicine and...
Study Examines Right-Sided vs Left-Sided Colon Cancer Survival Rates
Patients with colorectal cancer tumors on the right side may have poorer 5-year survival rates than those whose tumors are located on the left side. However, a new large-scale retrospective study is the first to demonstrate a potential improvement of these outcomes. Study results show that nearly...
FDA Approves Iobenguane I-131 for Rare Adrenal Gland Tumors
On July 30, the U.S. Food and Drug Administration (FDA) approved iobenguane I-131 (Azedra) injection for adult and pediatric patients (12 years and older) with iobenguane scan–positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (PPGL) who require systemic...
FDA Grants Fast Track Designation to Galinpepimut-S in Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to galinpepimut-S for the treatment of multiple myeloma. Galinpepimut-S is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms tumor 1 (WT1) protein, which is present in an array of tumor types....
FDA Approves Magnetic Device System for Guiding Sentinel Lymph Node Biopsies in Patients With Breast Cancer
The U.S. Food and Drug Administration (FDA) recently approved a magnetic device system for guiding lymph node biopsies in patients with breast cancer undergoing mastectomy. The Magtrace and Sentimag Magnetic Localization System uses magnetic detection during sentinel lymph node biopsy procedures to ...
Biomarker-Integrated Risk Model for Lung Cancer
As reported in JAMA Oncology by the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Consortium for Early Detection of Lung Cancer, incorporating biomarkers into a lung cancer risk prediction model may improve performance compared with risk based on age and smoking exposure alone....
New Study Calls for Continued Aggressive Treatment for Breast Cancer in Women Under 40
A new study from the Stanford Cancer Institute found that young women who are treated with chemotherapy for breast cancer but have residual tumor in either the breast or lymph nodes have higher chances of recurrence compared to those with no evidence of any residual invasive...
Robot-Assisted Laparoscopic Prostatectomy vs Open Radical Retropubic Prostatectomy in Newly Diagnosed Prostate Cancer
In an Australian phase III trial reported in The Lancet Oncology, Coughlin et al found similar functional outcomes at 2 years with robot-assisted laparoscopic prostatectomy and open radical retropubic prostatectomy in men with newly diagnosed clinically localized prostate cancer. Study Details In ...
IMpower 132: Atezolizumab in Combination With Pemetrexed and Platinum-Based Chemotherapy in Advanced Nonsquamous NSCLC
The phase III IMpower132 study met its co-primary endpoint of progression-free survival and demonstrated that the combination of atezolizumab (Tecentriq) plus chemotherapy (cisplatin or carboplatin plus pemetrexed [Alimta]) reduced the risk of disease worsening or death compared to chemotherapy...
Alan S. Rabson, MD, Long-Time NCI Deputy Director and Cancer Research Stalwart, Dies at Age 92
MANY IN the cancer research and National Institutes of Health (NIH) community are mourning the loss of long-time National Cancer Institute (NCI) senior leader Alan S. Rabson, MD, who died on July 4 at the age of 92. With a distinguished scientific career that spanned 6 decades and included...
